Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics starts zipalertinib NDA submission to FDA under RTOR program

Neutral Impact 3 of 5 product/contract Written later

Cullinan Therapeutics announced on October 1, 2026 that it has initiated a New Drug Application submission to the FDA for zipalertinib plus platinum-based chemotherapy in previously untreated EGFR exon 20 insertion NSCLC, under the FDA's Real-Time Oncology Review program. The company expects to complete the submission by year-end 2026, and the filing does not disclose financial results or a change in guidance. For shareholders, this is a regulatory milestone that also keeps milestone payments from partner Taiho in view.

Key points

  • NDA submission initiated on October 1, 2026 under the FDA's Real-Time Oncology Review program; completion expected by year-end 2026
  • Submission is based on Phase 3 REZILIENT3 trial data, which met its primary endpoint for median progression-free survival
  • A separate NDA for zipalertinib monotherapy remains under FDA review with a PDUFA target action date of February 27, 2027
  • Company is eligible for a $30.0 million payment from Taiho on U.S. approval in second-line treatment and up to $100.0 million on first-line approval

The filing

CompanyCullinan Therapeutics, Inc. (CGEM)
Form8-K, current report
Filed with the SECOct 1, 2026, 7:35 PM ET
Accession number0001193125-26-411011

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.